Drug Profile

Efocipegtrutide - Hanmi Pharmaceutical

Alternative Names: GLP-1/GIP/glucagon triagonist - Hanmi Pharmaceutical; HM-15211; LAPS-triple agonist

Latest Information Update: 05 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hanmi Pharmaceutical
Class Antidementias; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Antiparkinsonians; Hepatoprotectants; Immunoglobulin Fc fragments; Obesity therapies; Peptides; Recombinant fusion proteins
Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Primary sclerosing cholangitis; Idiopathic pulmonary fibrosis; Primary biliary cirrhosis
New Molecular Entity Yes
Available For Licensing Yes

Phase II Non-alcoholic steatohepatitis
Phase I Non-alcoholic fatty liver disease
Preclinical Hepatic fibrosis; Idiopathic pulmonary fibrosis
Discontinued Alzheimer's disease; Dyslipidaemias; Multiple sclerosis; Obesity; Parkinson's disease; Type 2 diabetes mellitus

05 Aug 2026 Efocipegtrutide is still in preclinical development in Idiopathic-pulmonary-fibrosis in South Korea (Hanmi Pharmaceuticals pipeline, August,
05 Aug 2026 Efocipegtrutide - Hanmi Pharmaceutical is available for licensing as of 05 Aug 2026. https://www.hanmipharm.com/science/pipeline/focused/efocipegtrutide.hm (Hanmi Pharmaceutical website, August 2026)
04 Aug 2026 Hanmi Pharmaceuticals plans a phase III trial for Non-alcoholic steatohepatitis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com